Average Out-of-Pocket Expenses Across Different Drug Categories and Commercial Third-Party Payers.
In this Trend Watch, we look at retail pharmacy prescriptions for branded and generic attention deficit hyperactivity disorder treatments, atypical antipsychotics, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors and analyze the average out-of-pocket cost...
| Published in: | Psychiatry (1550-5952) Vol. 7; no. 10; pp. 12 - 14 |
|---|---|
| Main Authors: | , |
| Format: | tables/charts Journal Article |
| Published: |
Matrix Medical Communications, LLC
Oct2010
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=55176442&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 55176442 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15505952 32GJ jtl: Psychiatry (1550-5952) issn: 15505952 maglogo: N pubinfo: dt: Oct2010 vid: 7 iid: 10 pid: 33670 pub: Matrix Medical Communications, LLC place: West Chester, Pennsylvania artinfo: ui: 55176442 55176442 105016958 55176442 ppf: 12 ppct: 2 formats: fmt: @attributes: type: P tig: atl: Average Out-of-Pocket Expenses Across Different Drug Categories and Commercial Third-Party Payers. aug: au: Lenderts, Susan Kalali, Amir H. affil: Associate Director, Global Commercial Partnering, Quintiles Commercial 4820 Emperor Blvd, Durham, NC 27703 sug: subj: Psychotropic Drugs Economics Drugs, Prescription Economics Mental Disorders Drug Therapy Insurance, Health, Reimbursement Attention Deficit Hyperactivity Disorder Drug Therapy Antipsychotic Agents Economics Serotonin Uptake Inhibitors Economics Managed Care Programs ab: In this Trend Watch, we look at retail pharmacy prescriptions for branded and generic attention deficit hyperactivity disorder treatments, atypical antipsychotics, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors and analyze the average out-of-pocket costs incurred by patients who are covered by commercial third-party prescription plans (i.e., as opposed to patients covered by Medicaid or patients with no prescription coverage). Overall, patient out-of-pocket costs in commercial third-party plans are lower for generic prescriptions than they are for brand prescriptions by at least $19.02. Comparisons across the drug classes reveal that the average co-pay for brands and generics, as well as the difference between brand and generic out-of-pocket costs, differ by drug category. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|